CSL (OTCMKTS:CSLLY) Sets New 52-Week Low on Analyst Downgrade

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price reached a new 52-week low on Monday after Zacks Research downgraded the stock from a hold rating to a strong sell rating. The company traded as low as $17.7765 and last traded at $18.1350, with a volume of 2722 shares changing hands. The stock had previously closed at $21.81.

Other research analysts have also issued reports about the stock. Citigroup lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a research report on Monday. Royal Bank Of Canada lowered shares of CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold”.

CSL Stock Down 1.9%

The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The business’s fifty day moving average price is $24.02 and its 200-day moving average price is $46.65.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.